Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Pharmaceutical TechnologyKOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.Clinical DataMetabolic & GLP-1Read full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalryNext: AZ claims another win for Imfinzi in frontline liver cancer Related Stories Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026 Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026 Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes pharminent June 9, 2026
